The binding properties of prostaglandin PGE and ACTH, and their action on adenylate cyclase activity (AC) have studied in 12 hormone producing tumors of the human adrenal cortex and compared with those found in the same type of subcellular preparation (20 000 xg) from normal human adrenal glands.
A specific binding of PGE and a stimulation of AC by this e and by NaF was obtained in all cases. A specific binding "rT9Bl-ACTH was also observed in all cases, but ACTH only stimulated AC in six cases. In the other six cases where AC was insensitive to ACTH, the steroidogenesis was not stimulated " i ivo " by this hormo However these tumors bound specifically " ' 1 -T'5 1 -ACT" the K being similar for both peptides ACTH1-?4 bu andtimes 1owe!'~6$A the o4e found in normal adrenal cortex for 'WI-ACTHI-24. This results strongly suggests the possibility of a modificat~on or a loss of the receptor site.which binds the N-terminal sequence (1-10) of ACTH known as the biologically active part of the molecule.
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{ . v. c h n aIre;~:''re and i'. ,nonrr L n i v e r s i t ' i t s -i i i n d e r i i l i n i k ?:unchen, Germany These parameters were determined in 34 children and adolescents with C-21 AH, during 2 years period. Blood samples were obtained between 6 and 9 a.m. on fasting individuals after one night of rest at the hospital. Elevated levels of T were observed before treatment or when the glucocorticoid doses were in sufficient. In some cases, starting or raising the mineralocorticoid treatment (9 alpha fluorocortisol) was followed by a decrease in T levels.
High levels of R. A. were constantly found before treatment, even in the absence of salt losing syndrome. In some cases treated by glucocorticoid and salt, R.A. levels remained elevated: appropriated doses of 9 alpha fluorocortisol,induced a marked decrease in R.A. levels. Elevatebl 17-OH levels were always present before treatment, but frequently failed to normalize under therapy. Important individual variations were ibserved from day today and in the same day. As far as ACTH is concerned, our data are too inconsistnet to take into account this parameter. Regular determinations of plasma T and R. A. allow us a better control of glucocorticoid therapy (our mean dose being 19 mg hydrocortisone/m2/day which is lower than dosages usually published) and of skeletal maturation (however, none of this infants followed since birth are older than two years). sampled between 8 and 10 a.m., durina a normal sodium intake had a mean PA value of 20.6 2 2.4 (SEMI pg/ml (basal levels).
!The increase in PA after IM injection o f~l -2 4 ACTH (250 pg)
waa 500 to 2000 % (9 subjects) and after five days of,lor sodium intake (LSI) it was 457 to 1220 % (5 subjects). In 12 infants aged 1 to 12 months, the mean basal PA was 102 pg/ml (range 19 to 171 pg/ml). Among the 20 children with congenital adrenal hyperplasia, 4 salt loosers were studied before any treatment during the first month of life, while they were suffering from sn acute salt depletion. Their PA were lower than 50 pg/ml. Sixteen 2 to 9 year old patients never had clinical symptoms of salt depletion. While 8 of these
were not under treatment, basal PA were elevated (40 to 320 pg/ml). The LSI and the ACTH injection induced variable but 'limited increases in PA. Since the biosynthesls of Aldosterone appears to be limited, these patients may be considered potential salt loosers. When treated with cortisol, the PA levels decreased and a positive correlation ( pd0.001) be- In Addison's disease, very low levels of DHEA were found although pubertal development hatl started. In 6 girls with treated congenital virilizing adrenal hyperplasia, normal to hieh levels of DHEA and T were observed. In 2 cases with -Gushing's syndrome, very high lev,els of DKEA decreased wlth therapy to normal or low levels. levels and the increases in PA during LSI were 300 to 1100 %, kith normal sodium balances. A deficiency progressively affecting diverse adrenocortical functions is discussed.
